Skip to main content

Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma.

Publication ,  Journal Article
Jia, Q; Qin, D; He, F; Xie, Q; Ying, Z; Zhang, Y; Song, Y; Cheng, J-N; Zuo, X; Xu, L; Fang, H; Hu, C; Peng, L; Jin, T; Shi, Z; Wang, Y ...
Published in: Theranostics
2021

Rationale: The onset of cytokine release syndrome (CRS) and in vivo persistence of anti-CD19 chimeric antigen receptor T (CAR-T) cells after infusion correlate with clinical responsiveness. However, there are no known baseline biomarkers that can predict the prognosis of patients with B-lineage non-Hodgkin lymphoma (B-NHL). The aim of this study was to identify blood cell populations associated with beneficial outcomes in B-NHL patients administered CAR-T cell immunotherapies. Methods: We enumerated peripheral blood and CAR-T cells by retrospectively analyzing three CAR-T cell trials involving 65 B-NHL patients. We used a preclinical model to elucidate the eosinophil mechanism in CAR-T cell therapy. Results: During an observation period up to 30 mo, B-NHL patients with higher baseline eosinophil counts had higher objective response rates than those with low eosinophil counts. Higher baseline eosinophil counts were also significantly associated with durable progression-free survival (PFS). The predictive significance of baseline eosinophil counts was validated in two independent cohorts. A preclinical model showed that eosinophil depletion impairs the intratumoral infiltration of transferred CAR-T cells and reduces CAR-T cell antitumor efficacy. Conclusion: The results of this study suggest that peripheral eosinophils could serve as stratification biomarkers and a recruitment machinery to facilitate anti-CD19 CAR-T cell therapy in B-NHL patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Theranostics

DOI

EISSN

1838-7640

Publication Date

2021

Volume

11

Issue

10

Start / End Page

4699 / 4709

Location

Australia

Related Subject Headings

  • Young Adult
  • Receptors, Chimeric Antigen
  • Progression-Free Survival
  • Prognosis
  • Middle Aged
  • Mice
  • Male
  • Lymphoma, B-Cell
  • Leukocyte Count
  • Immunotherapy, Adoptive
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jia, Q., Qin, D., He, F., Xie, Q., Ying, Z., Zhang, Y., … Zhu, B. (2021). Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma. Theranostics, 11(10), 4699–4709. https://doi.org/10.7150/thno.54546
Jia, Qingzhu, Diyuan Qin, Feng He, Qichao Xie, Zhitao Ying, Yajing Zhang, Yuqin Song, et al. “Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma.Theranostics 11, no. 10 (2021): 4699–4709. https://doi.org/10.7150/thno.54546.
Jia Q, Qin D, He F, Xie Q, Ying Z, Zhang Y, et al. Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma. Theranostics. 2021;11(10):4699–709.
Jia, Qingzhu, et al. “Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma.Theranostics, vol. 11, no. 10, 2021, pp. 4699–709. Pubmed, doi:10.7150/thno.54546.
Jia Q, Qin D, He F, Xie Q, Ying Z, Zhang Y, Song Y, Cheng J-N, Zuo X, Xu L, Fang H, Hu C, Peng L, Jin T, Shi Z, Alexander PB, Wang Y, Liu Y, Han W, Zhu J, Wang P, Li Q-J, Zhu B. Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma. Theranostics. 2021;11(10):4699–4709.

Published In

Theranostics

DOI

EISSN

1838-7640

Publication Date

2021

Volume

11

Issue

10

Start / End Page

4699 / 4709

Location

Australia

Related Subject Headings

  • Young Adult
  • Receptors, Chimeric Antigen
  • Progression-Free Survival
  • Prognosis
  • Middle Aged
  • Mice
  • Male
  • Lymphoma, B-Cell
  • Leukocyte Count
  • Immunotherapy, Adoptive